Title
Renal Ischemia Regulates Marinobufagenin Release in Humans
Document Type
Article
Publication Date
Fall 8-11-2010
Abstract
Cardiotonic steroids, including marinobufagenin, are a group of new steroid hormones found in plasma and urine of patients with congestive heart failure, myocardial infarction, and chronic renal failure. In animal studies, partial nephrectomy induces marinobufagenin elevation, cardiac hypertrophy, and fibrosis. The objective of this study is to test the effect of renal ischemia on marinobufagenin levels in humans with renal artery stenosis (RAS). To test this, plasma marinobufagenin levels were measured in patients with RAS of the Prospective Randomized Study Comparing Renal Artery Stenting With or Without Distal Protection, non-RAS patient controls who were scheduled for coronary angiography, and normal healthy individuals. Marinobufagenin levels were significantly higher in patients with RAS compared with those of the other 2 groups. Multivariate analysis shows that occurrence of RAS is independently related to marinobufagenin levels. In addition, renal artery revascularization by stenting partially reversed marinobufagenin levels in the patients with RAS (0.77+0.06 nmol/L at baseline; 0.66+0.06 nmol/L at 24 hours; and 0.61+0.05 nmol/L at 1 month). In conclusion, we have found that marinobufagenin levels are increased in patients with RAS, whereas reversal of renal ischemia by stenting treatment reduces marinobufagenin levels. These results suggest that RAS-induced renal ischemia may be a major cause of marinobufagenin release.
Recommended Citation
Tian J, Haller S, Periyasamy S, Brewster P, Zhang H, Adlakha S, Fedorova OV, Xie ZJ, Bagrov AY, Shapiro JI, et al. (2010) Renal ischemia regulates marinobufagenin release in humans. Hypertension 56, 914–919.
Comments
The copy of record is available from the American Heart Association at http://hyper.ahajournals.org/content/56/5/914.full.pdf. Copyright © 2010 American Heart Association, Inc. DOI: 10.1161/HYPERTENSIONAHA.110.155564